Q-omics provides the consensus-scored HRH3 profile across patient tissues and cancer cell-line models. HRH3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HRH3 is differentially expressed in 9, with the highest sampling consensus in UCEC. Additionally, HRH3 RNA expression shows 10,968 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, UCEC, and TGCT as cancer lineages where HRH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HRH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HRH3 survival associations across molecular data types. HRH3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HRH3 RNA expression–survival associations across cancer types. High HRH3 expression shows unfavorable associations in KIRC, STAD, KIRP and LIHC, but favorable associations in PAAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HRH3 RNA expression.
This table summarizes HRH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in UCEC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HRH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HRH3 shows lower tumor expression in HNSC and higher tumor expression in UCEC, BRCA, LUSC, CHOL and LIHC. The UCEC box plot shows higher HRH3 RNA expression in tumor versus normal tissue (log2 FC = +0.289, t-test p = .004).
This table shows molecular features associated with HRH3 in patient tissues and cancer cell lines. In patient samples, HRH3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HRH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
